Achieve Life Sciences Stock (NASDAQ:ACHV)

Forecast Ownership Financials Chart Transcripts

Previous Close

$2.68

52W Range

$1.84 - $5.31

50D Avg

$3.03

200D Avg

$3.38

Market Cap

$133.65M

Avg Vol (3M)

$867.80K

Beta

1.51

Div Yield

-

ACHV Company Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

25

IPO Date

Oct 12, 1995

Website

ACHV Performance

ACHV Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-27.25M	$-40.80M
Net Income	$-39.83M	$-29.82M	$-41.88M
EBITDA	-	$-26.73M	$-40.33M
Basic EPS	$-1.24	$-1.50	$-3.95
Diluted EPS	$-1.24	$-1.50	$-3.95

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 13, 25 | 8:30 AM

Q4 24Mar 11, 25 | 8:30 AM

Q3 24Nov 09, 24 | 4:30 PM

Peer Comparison

Ticker	Company
DARE	Daré Bioscience, Inc.
XBIO	Xenetic Biosciences, Inc.
BOLT	Bolt Biotherapeutics, Inc.
PRPO	Precipio, Inc.
CAPR	Capricor Therapeutics, Inc.
ANNX	Annexon, Inc.
LYRA	Lyra Therapeutics, Inc.
AKTX	Akari Therapeutics, Plc